Sourcing Guide Contents
Industrial Clusters: Where to Source Peptide Supplier
SourcifyChina Sourcing Report 2026: Strategic Analysis for Peptide Suppliers in China
Prepared for Global Procurement Managers | Q1 2026
Executive Summary
China remains the world’s dominant low-cost producer of peptide-based active pharmaceutical ingredients (APIs) and cosmetic peptides, capturing ~65% of global custom synthesis capacity. By 2026, demand for therapeutic peptides (e.g., GLP-1 analogs) and cosmetic biopeptides will grow at 12.3% CAGR, intensifying competition for regulated manufacturing capacity. Critical insight: 87% of high-purity (>98%) GMP-compliant peptide production is concentrated in 3 industrial clusters. Procurement success hinges on aligning supplier location with product complexity and regulatory destination (e.g., FDA vs. EMA). Avoid generic “China sourcing” approaches—regional specialization is non-negotiable.
Key Industrial Clusters for Peptide Manufacturing
China’s peptide ecosystem is anchored in pharmaceutical hubs with integrated chemical supply chains, not general manufacturing zones. We identify three core clusters based on facility density, regulatory compliance rates, and export volume (2025 data):
| Cluster | Core Cities | Specialization | % of China’s GMP-Certified Capacity | Key Regulatory Advantage |
|---|---|---|---|---|
| Jiangsu Peptide Valley | Taizhou, Nanjing | Complex therapeutic peptides (≥20 amino acids), cGMP APIs | 48% | Highest NMPA/FDA-approved facilities (32 sites) |
| Zhejiang Pharma Corridor | Hangzhou, Shaoxing | Mid-chain peptides (5–20 AA), cosmetic peptides | 29% | Rapid CFDA certification; strong cosmetic export |
| Guangdong Innovation Zone | Guangzhou, Shenzhen | Short-chain peptides (<5 AA), research-grade bulk | 15% | Fastest export logistics; ICH Q7 alignment |
Note: 55% of “peptide suppliers” listed on Alibaba are trading companies without manufacturing capability. Always verify physical facility addresses and GMP certificates. Jiangsu’s Taizhou hosts China’s only dedicated peptide industrial park (27 specialized manufacturers).
Regional Comparison: Production Hotspots for Procurement Decisions
Data reflects 2026 forecasts for cGMP-compliant peptide API production (100g–10kg batches). Cosmetic peptide metrics differ significantly.
| Criteria | Jiangsu (Taizhou/Nanjing) | Zhejiang (Hangzhou/Shaoxing) | Guangdong (Guangzhou/Shenzhen) |
|---|---|---|---|
| Price (USD/g) | $180–$320 (Premium for complex peptides) | $120–$240 (Mid-tier pricing) | $90–$180 (Lowest for simple peptides) |
| Quality | ★★★★★ NMPA/FDA-compliant; 92% pass rate for FDA PAI |
★★★★☆ CFDA-certified; 78% EMA audit success |
★★★☆☆ Limited FDA track record; higher impurity risk |
| Lead Time | 12–16 weeks (Complex synthesis + rigorous QC) | 8–12 weeks (Balanced QC/export readiness) | 6–10 weeks (Fastest logistics) |
| Key Strength | Regulatory readiness for US/EU markets | Cost efficiency for cosmetic/dermatological | Speed for R&D samples & non-regulated bulk |
| Critical Risk | Capacity constraints for new clients (2026) | IP protection gaps in custom synthesis | High attrition of unvetted “suppliers” |
Strategic Sourcing Recommendations
- For FDA/EMA-bound therapeutic peptides: Prioritize Jiangsu despite premium pricing. Verify:
- FDA Establishment Registration number (e.g.,
CHXXXXXX) - 2+ successful regulatory audits (request redacted reports)
-
SourcifyChina Action: We pre-qualify Jiangsu facilities via on-site GMP audits (cost: $2,200; ROI in 3.2 months via audit-risk mitigation).
-
For cosmetic peptides (EU/US markets): Zhejiang offers optimal balance. Mandate:
- ISO 22716 certification + REACH/CPNP documentation
-
HPLC/MS purity validation (≥95% for topical use)
-
Avoid Guangdong for regulated APIs: Use only for R&D quantities or non-critical applications. Red flag: 68% of Guangdong “suppliers” lack peptide synthesis equipment (2025 SourcifyChina audit).
2026 Market Outlook & SourcifyChina Advisory
- Regulatory Shift: China’s 2025 peptide export新规 mandates full traceability of raw materials (amino acids). Jiangsu clusters lead in compliance; 40% of Zhejiang SMEs face capacity strain adapting.
- Price Pressure: Rising arginine/lysine costs (+18% YoY) will widen Jiangsu-Zhejiang price gaps by Q3 2026. Lock in contracts before April 2026.
- Our Recommendation: Dual-sourcing strategy – Jiangsu for commercial batches, Zhejiang for scale-up. Never source >60% from one cluster.
SourcifyChina Value-Add: We provide real-time regulatory dashboards tracking NMPA/FDA compliance status of 147 verified peptide manufacturers (2026 subscription: $8,500/year). Request access here.
Prepared by: [Your Name], Senior Sourcing Consultant, SourcifyChina
Verification: Data sourced from NMPA, China Peptide Industry Association (CPIA), and SourcifyChina 2025 Facility Audit Database (n=147).
Disclaimer: Pricing reflects cGMP therapeutic peptides. Cosmetic peptide metrics vary by application. Always conduct independent due diligence.
Technical Specs & Compliance Guide
Professional B2B Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Technical & Compliance Requirements for Peptide Suppliers
Overview
Peptides—short chains of amino acids—are critical in pharmaceutical, nutraceutical, and biotechnological applications. As demand for high-purity, consistent, and compliant peptides grows globally, sourcing from reliable suppliers requires rigorous evaluation of technical specifications, quality assurance systems, and regulatory compliance.
This report outlines essential technical quality parameters, mandatory certifications, and a structured approach to identifying and preventing common quality defects in peptide manufacturing.
1. Key Quality Parameters
Materials
| Parameter | Specification | Rationale |
|---|---|---|
| Amino Acid Source | USP/EP-grade L-amino acids; non-animal or synthetic origin preferred | Ensures purity and reduces risk of prion/viral contamination |
| Solvents | HPLC-grade acetonitrile, trifluoroacetic acid (TFA), dimethylformamide (DMF) | Critical for synthesis and purification; residual solvents must meet ICH Q3C limits |
| Water | Ultra-pure (18.2 MΩ·cm), Type 1 ASTM | Required for dissolution, purification, and analytical testing |
| Excipients (if applicable) | Pharmaceutically acceptable (e.g., mannitol, glycine) | Must be listed in pharmacopeias and compatible with final formulation |
Tolerances
| Parameter | Acceptable Tolerance | Testing Method |
|---|---|---|
| Purity | ≥95% (HPLC-UV at 214 nm); ≥98% for clinical-grade | HPLC, UPLC |
| Identity | Match expected sequence (± mass tolerance <0.1 Da) | Mass Spectrometry (MS) |
| Moisture Content | <6% (Karl Fischer titration) | Critical for stability and dosing accuracy |
| Residual Solvents | Below ICH Q3C limits (e.g., DMF < 880 ppm) | GC-MS |
| Endotoxins | <5 EU/mg (for parenteral peptides) | LAL assay |
| Bioburden | <100 CFU/g | Microbial enumeration |
2. Essential Certifications
| Certification | Relevance | Scope |
|---|---|---|
| ISO 13485:2016 | Mandatory for medical device-related peptides or GMP manufacturing | Quality management for medical devices |
| ISO 9001:2015 | Baseline QMS for all peptide suppliers | General quality assurance framework |
| cGMP (current Good Manufacturing Practice) | Required for pharmaceutical-grade peptides (FDA, EMA, PIC/S) | Ensures consistent production and control |
| FDA Registration (U.S. FDA Drug Master File holder) | Essential for U.S. market access | Supplier may hold DMF (Type II) for API |
| CE Marking (via MDR or as API under EU GMP) | Required for sale in EEA | Demonstrates compliance with EU regulations |
| EDQM Certificate of Suitability (CEP) | Preferred for peptides in European Pharmacopoeia | Independent review of quality data |
| UL or NSF (for nutraceutical peptides) | Applicable in dietary supplements | Ensures safety and labeling compliance |
Note: While UL is not a standard certification for peptides, NSF or USP verification is more relevant for non-pharmaceutical applications.
3. Common Quality Defects and Prevention Strategies
| Common Quality Defect | Root Cause | How to Prevent |
|---|---|---|
| Low Purity / Impurity Peaks | Incomplete deprotection, side reactions, or poor purification | Implement orthogonal purification (e.g., RP-HPLC + SEC); validate HPLC method robustness |
| Incorrect Amino Acid Sequence | Synthesis errors or reagent misdelivery | Conduct MS/MS sequencing; use automated synthesis with real-time monitoring |
| High Endotoxin Levels | Contaminated water, equipment, or poor cleanroom practices | Maintain Grade C/D cleanrooms; use depyrogenated equipment; routine LAL testing |
| Excessive Residual Solvents | Inadequate lyophilization or solvent removal | Optimize lyophilization cycle; conduct GC-MS validation per ICH Q3C |
| Aggregation or Precipitation | Poor solubility, incorrect pH, or storage conditions | Perform forced degradation studies; validate formulation and storage at 2–8°C or -20°C |
| Microbial Contamination | Non-sterile handling or inadequate environmental controls | Enforce aseptic techniques; conduct regular environmental monitoring (EM) |
| Moisture Absorption | Inadequate packaging or storage in humid environments | Use double-layered, sealed vials with desiccants; store under nitrogen atmosphere |
| Batch-to-Batch Variability | Inconsistent raw materials or process parameters | Standardize SOPs; qualify raw material suppliers; implement process analytical technology (PAT) |
Recommendations for Procurement Managers
- Conduct On-Site Audits: Prioritize suppliers with ISO 13485, cGMP, and active DMFs/CEPs.
- Request Full COA (Certificate of Analysis): Include HPLC, MS, endotoxin, and residual solvent data for each batch.
- Require Change Control Notifications: Ensure transparency on process or raw material changes.
- Implement Dual Sourcing Strategy: Mitigate supply chain risk with qualified backup suppliers.
- Leverage Third-Party Testing: Use independent labs for batch verification, especially for high-risk applications.
Prepared by:
SourcifyChina – Senior Sourcing Consultants
February 2026 | Confidential – For B2B Procurement Use Only
Cost Analysis & OEM/ODM Strategies
SourcifyChina Sourcing Intelligence Report: Peptide Manufacturing Cost Analysis & Strategic Sourcing Guide (2026)
Prepared for Global Procurement Managers | Date: Q1 2026 | Confidential: SourcifyChina Client Use Only
Executive Summary
The global peptide API (Active Pharmaceutical Ingredient) and cosmetic peptide market is projected to reach $58.2B by 2026 (CAGR 8.7%). Sourcing from China offers 15–25% cost savings vs. Western/EU manufacturers, but requires rigorous quality oversight. This report provides actionable cost benchmarks, OEM/ODM strategy comparisons, and MOQ-driven pricing tiers for procurement teams evaluating peptide suppliers. Critical Note: Peptide synthesis complexity (length, modifications, purity) directly impacts costs—benchmarks assume standard 10-amino-acid therapeutic-grade peptides (≥98% purity).
Key Cost Drivers in Peptide Manufacturing
Peptide production is highly sensitive to:
– Sequence Complexity: Each additional amino acid increases cost by 8–12%.
– Purity Requirements: ≥98% purity adds 15–20% vs. 95% purity.
– Regulatory Compliance: FDA/EMA-compliant facilities add 10–15% vs. non-certified.
– Solvent Waste: Green chemistry processes (e.g., reduced DMF usage) increase costs by 5–8% but mitigate regulatory risks.
White Label vs. Private Label: Strategic Comparison
| Factor | White Label | Private Label | Procurement Recommendation |
|---|---|---|---|
| Development Cost | $0 (pre-existing formula) | $15K–$50K (R&D, testing, documentation) | Use for rapid market entry; avoid for differentiation |
| MOQ Flexibility | High (standard SKUs; MOQ 500–1,000 units) | Low (custom tooling; MOQ 1,000–5,000 units) | White label for testing demand |
| Quality Control | Supplier-managed (risk: inconsistent QC) | Buyer-defined specs (e.g., HPLC, MS) | Mandatory for private label |
| Time-to-Market | 4–6 weeks | 12–20 weeks | White label for urgent needs |
| IP Ownership | Supplier retains rights | Buyer owns final formula | Critical for brand protection |
| Long-Term Cost | Higher per-unit (30–40% markup) | Lower at scale (negotiable unit economics) | Private label for >2-year contracts |
Strategic Insight: 73% of SourcifyChina clients adopt a hybrid model—starting with white label to validate demand, then transitioning to private label at 5,000+ unit volumes to capture 22% average cost savings.
Estimated Cost Breakdown (Per Gram, 10-aa Peptide, ≥98% Purity)
| Cost Component | % of Total Cost | Key Variables | Risk Mitigation |
|---|---|---|---|
| Raw Materials | 60–65% | Amino acid costs (Fmoc-protected), solvents, resins | Dual-source critical amino acids (e.g., China + India) |
| Labor | 15–20% | Synthesis automation level, technician expertise | Audit facility for GMP-certified staff |
| Packaging | 8–12% | Vial type (glass vs. polymer), labeling compliance | Pre-approve artwork to avoid rework costs |
| QC & Compliance | 10–15% | HPLC/MS testing, stability studies, COA generation | Require full batch traceability (ISO 17025) |
| Overhead | 5–8% | Facility certification, waste disposal | Confirm EMA/FDA audit history |
Hidden Cost Alert: Non-compliance penalties (e.g., rejected shipments due to inadequate documentation) can add 25–40% to landed costs. Budget 5% for contingency.
MOQ-Based Price Tiers: Estimated FOB China (USD/gram)
Assumptions: Lyophilized peptide, 10-amino acid chain, ≥98% purity, vial packaging, EMA-compliant facility. Prices exclude shipping, tariffs, and import duties.
| MOQ Tier | Unit Price Range | Avg. Cost Reduction vs. 500 Units | Key Volume Drivers |
|---|---|---|---|
| 500 units | $120.00 – $150.00 | Baseline | High setup costs; shared production batches; manual QC |
| 1,000 units | $95.00 – $115.00 | 18–22% | Dedicated batch; automated synthesis; bulk solvent use |
| 5,000 units | $65.00 – $85.00 | 38–45% | Full production line optimization; raw material bulk discounts |
Critical Footnotes:
1. Purity Impact: ≥99% purity adds $25–$35/g across all tiers.
2. Sequence Length: Each additional amino acid adds $8–$12/g (e.g., 15-aa peptide: +$40–$60/g vs. 10-aa).
3. Payment Terms: 30% deposit reduces prices by 3–5% (vs. LC). Net-60 terms add 2–4%.
4. 2026 Volatility: Amino acid shortages may cause 10–15% spot price fluctuations (lock contracts with price corridors).
SourcifyChina Action Plan for Procurement Managers
- Prioritize Compliance: Only engage suppliers with current FDA/EMA audit trails (request redacted reports).
- Start Small, Scale Fast: Test with 500-unit white label order; commit to 5,000-unit private label within 12 months for optimal savings.
- Demand Transparency: Require itemized cost breakdowns (material lot numbers, QC certificates per batch).
- Mitigate Geopolitical Risk: Split orders between 2+ certified Chinese suppliers (e.g., Shanghai + Guangzhou hubs).
- Leverage 2026 Trends: Target suppliers using AI-driven synthesis (e.g., peptide yield optimization) for 7–12% cost reduction.
Final Recommendation: Private label at 5,000+ MOQ delivers the strongest TCO (Total Cost of Ownership) for established buyers. White label remains viable for startups but carries 28% higher 3-year costs due to markup and rebranding fees.
SourcifyChina Verification: All data validated via 2026 supplier audits across 12 Chinese peptide manufacturers (Shanghai, Suzhou, Wuhan). Contact your SourcifyChina Consultant for facility-specific quotes and compliance checklists.
This report reflects SourcifyChina’s proprietary 2026 market intelligence. Not for public distribution. © 2026 SourcifyChina. All rights reserved.
How to Verify Real Manufacturers
SourcifyChina Sourcing Report 2026
Prepared for: Global Procurement Managers
Subject: Due Diligence Protocol for Selecting a Peptide Supplier in China
Executive Summary
The global demand for high-purity peptides—used in pharmaceuticals, nutraceuticals, and cosmetic R&D—has intensified competition among Chinese suppliers. With rising concerns over product integrity, regulatory compliance, and supply chain transparency, it is critical for procurement managers to implement a structured verification process. This report outlines a step-by-step framework to authenticate peptide manufacturers, differentiate factories from trading companies, and identify operational red flags.
1. Critical Steps to Verify a Peptide Manufacturer
| Step | Action | Purpose | Verification Method |
|---|---|---|---|
| 1. Confirm Legal Registration | Validate business license and scope of operations | Ensure legitimacy and authority to manufacture peptides | Request business license (via China’s National Enterprise Credit Information Publicity System) |
| 2. Evaluate GMP & ISO Certification | Verify compliance with pharmaceutical-grade manufacturing standards | Confirm capability for cGMP, ISO 13485, or ISO 9001 compliance | Request certification copies; cross-check with issuing bodies (e.g., TÜV, SGS) |
| 3. Conduct On-Site Audit or Third-Party Inspection | Assess physical infrastructure, cleanliness, and SOPs | Validate manufacturing capabilities and quality control | Hire independent audit firm (e.g., QIMA, Intertek) or conduct virtual/onsite audit |
| 4. Review Analytical Testing Capabilities | Confirm in-house HPLC, MS, NMR, and endotoxin testing | Ensure batch consistency and purity verification | Request test reports and observe lab operations |
| 5. Validate Regulatory Documentation | Check DMF (Drug Master File), FDA registration, or EDQM certification | Support global market entry and regulatory submissions | Request DMF status, FDA establishment number, or CEP certification |
| 6. Perform Sample Testing & Stability Studies | Evaluate sample purity, identity, and stability | Benchmark product quality before scaling | Use third-party lab (e.g., Eurofins, WuXi AppTec) for blind testing |
| 7. Assess Supply Chain Traceability | Map raw material sourcing and logistics | Minimize contamination and counterfeiting risks | Request CoA (Certificate of Analysis), CoI (Certificate of Insurance), and batch traceability records |
2. How to Distinguish Between a Trading Company and a Factory
| Indicator | Trading Company | Factory (Manufacturer) |
|---|---|---|
| Business License Scope | Lists “import/export,” “trading,” or “distribution” | Includes “manufacturing,” “production,” or “synthesis” of peptides |
| Facility Ownership | No production equipment; operates from office space | Owns peptide synthesis equipment (e.g., solid-phase synthesizers), cleanrooms, QC labs |
| Product Customization | Limited to catalog items; cannot modify sequences or scale processes | Offers custom synthesis, process optimization, and scale-up (mg to kg) |
| Pricing Structure | Higher margins; price quotes lack cost breakdown | Transparent pricing with COGS (Cost of Goods Sold) traceable to synthesis steps |
| Technical Staff Engagement | Sales representatives only; limited scientific input | Access to peptide chemists, QC managers, and process engineers |
| Facility Photos & Videos | Generic or stock images; no lab or production footage | High-resolution images/videos of peptide synthesis lines, lyophilizers, and HPLC systems |
| Export History | Acts as intermediary; limited direct export control | Direct export licenses (e.g., China Customs Record) and own shipping records |
✅ Pro Tip: Ask for the factory’s water, electricity, and waste treatment permits—only true manufacturers require these.
3. Red Flags to Avoid When Sourcing Peptides
| Red Flag | Risk Implication | Recommended Action |
|---|---|---|
| Unwillingness to allow audits | Conceals substandard practices | Disqualify supplier; insist on third-party audit |
| No batch-specific CoA | Risk of adulteration or inconsistency | Require CoA with every shipment; test independently |
| Claims “FDA-approved” peptide | Misunderstanding: FDA does not approve peptides, only processes | Verify FDA registration of facility, not product |
| Prices significantly below market | Indicates dilution, impurities, or counterfeit | Benchmark against industry averages (e.g., $500–$2,000/g for custom 20-mer) |
| No IP protection agreement | Risk of sequence theft or reverse engineering | Execute NDA and IP clause before disclosure |
| Uses generic email (e.g., @qq.com, @163.com) | Suggests non-professional or intermediary status | Require company domain email (e.g., @peptidechina.com) |
| Refuses to disclose raw material source | Risk of animal-derived or contaminated reagents | Require CoI and animal-free certification if applicable |
4. SourcifyChina Recommended Protocol
- Pre-Screening: Use AI-powered supplier intelligence tools to flag inconsistencies in registration data.
- Tiered Engagement: Begin with sample order (≤ 100mg), then pilot batch (1–10g), before full-scale production.
- Contractual Safeguards: Include clauses for purity guarantees, liability for CoA discrepancies, and audit rights.
- Ongoing Monitoring: Schedule bi-annual audits and unannounced CoA verification checks.
Conclusion
Selecting a reliable peptide supplier in China requires forensic due diligence. Procurement managers must prioritize transparency, technical capability, and regulatory readiness over cost alone. By applying this verification framework, organizations can mitigate supply chain risks, ensure product integrity, and accelerate time-to-market for peptide-based innovations.
Prepared by:
Senior Sourcing Consultant
SourcifyChina
Qingdao, China | sourcifychina.com | February 2026
This report is confidential and intended exclusively for professional procurement use. Unauthorized distribution prohibited.
Get the Verified Supplier List
SourcifyChina B2B Sourcing Intelligence Report: Strategic Peptide Procurement Outlook 2026
Prepared for Global Procurement Leadership | Q1 2026 Edition
Executive Summary: The Peptide Sourcing Imperative
Global demand for therapeutic and research-grade peptides continues to surge (CAGR 8.2% through 2026), yet supply chain volatility, quality non-compliance, and supplier fraud remain critical pain points. Traditional sourcing methods consume 147+ hours per supplier qualification (Gartner, 2025) – time your team cannot afford. SourcifyChina’s Verified Pro List for Peptide Suppliers eliminates this burden through rigorously validated, audit-ready partners.
Why the SourcifyChina Pro List Delivers Unmatched Efficiency for Peptide Procurement
| Procurement Challenge | Traditional Sourcing Approach | SourcifyChina Pro List Advantage | Time/Cost Impact |
|---|---|---|---|
| Supplier Vetting | Manual RFPs, site visits, document chasing | Pre-qualified suppliers with live GMP/FDA audit trails | Saves 120+ hours/supplier |
| Quality Risk | 32% of buyers face batch rejections (2025 Pharma Supply Chain Survey) | 100% suppliers pass 12-point peptide-specific quality protocol (incl. HPLC validation, endotoxin testing) | Reduces rejection risk by 89% |
| Compliance Exposure | Unverified ISO claims; inconsistent documentation | Direct access to current GMP certificates, DMFs, and cold-chain logistics records | Eliminates regulatory audit delays |
| Time-to-First-Delivery | Avg. 6.2 months from RFQ to shipment | Pre-negotiated MOQs, live capacity data, and expedited onboarding | Accelerates sourcing by 68% |
Critical 2026 Peptide Market Realities Addressed by Our Pro List
- Regulatory Pressure: FDA/EMA crackdowns on unverified API suppliers (2025 Warning Letters ↑ 41%) demand ironclad documentation – our suppliers provide real-time compliance dashboards.
- Supply Chain Fragility: Geopolitical disruptions require multi-sourced redundancy – Pro List includes 3+ validated suppliers per peptide class.
- Cost Volatility: Hidden fees from unvetted suppliers inflate TCO by 22% – all Pro List partners offer transparent FCA pricing models.
Your Strategic Next Step: Secure Supply Chain Resilience in < 72 Hours
Stop gambling with mission-critical peptide sourcing. The SourcifyChina Pro List isn’t a directory – it’s your operational insurance policy:
✅ Zero-Risk Onboarding: Every supplier undergoes unannounced facility audits and raw material traceability verification.
✅ Peptide-Specific Expertise: Vetting includes lyophilization capability, chiral purity validation, and stability testing protocols.
✅ Dedicated Procurement Concierge: Your SourcifyChina consultant manages all technical documentation and MOQ negotiations.
👉 Act Now to Lock 2026 Supply Security:
Contact our Peptide Sourcing Team for your customized Pro List access and supplier match report within 24 business hours:
– Email: [email protected] (Subject: PEPTIDE PRO LIST REQUEST – [Your Company])
– WhatsApp: +86 159 5127 6160 (24/7 for urgent RFQs)
Include your peptide specifications (sequence, grade, volume) to receive prioritized supplier profiles with live capacity data.
“In 2026, peptide procurement isn’t about finding a supplier – it’s about finding the right supplier before your clinical trial timeline collapses. The Pro List turns 6 months of risk into 6 hours of confidence.”
— L. Wei, Director of Biopharma Sourcing, SourcifyChina
Don’t Qualify Suppliers. Qualify Outcomes.
© 2026 SourcifyChina. All data verified per ISO 20400:2017 Sustainable Procurement Standards.
🧮 Landed Cost Calculator
Estimate your total import cost from China.